JP2023522193A5 - - Google Patents
Info
- Publication number
- JP2023522193A5 JP2023522193A5 JP2022562752A JP2022562752A JP2023522193A5 JP 2023522193 A5 JP2023522193 A5 JP 2023522193A5 JP 2022562752 A JP2022562752 A JP 2022562752A JP 2022562752 A JP2022562752 A JP 2022562752A JP 2023522193 A5 JP2023522193 A5 JP 2023522193A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antigen
- cells
- pool
- immunogenic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20170255.2 | 2020-04-17 | ||
| EP20170255 | 2020-04-17 | ||
| PCT/GB2021/050940 WO2021209775A1 (en) | 2020-04-17 | 2021-04-19 | Antigen pool |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023522193A JP2023522193A (ja) | 2023-05-29 |
| JP2023522193A5 true JP2023522193A5 (enExample) | 2024-05-20 |
Family
ID=70333816
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022562752A Pending JP2023522193A (ja) | 2020-04-17 | 2021-04-19 | 抗原プール |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230302109A1 (enExample) |
| EP (1) | EP4136096A1 (enExample) |
| JP (1) | JP2023522193A (enExample) |
| CN (1) | CN115667288A (enExample) |
| CA (1) | CA3176754A1 (enExample) |
| WO (1) | WO2021209775A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025202937A1 (en) | 2024-03-26 | 2025-10-02 | BioNTech SE | Cancer vaccines |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0871747A1 (en) | 1996-01-02 | 1998-10-21 | Chiron Viagene, Inc. | Immunostimulation mediated by gene-modified dendritic cells |
| US6770456B1 (en) | 1998-07-29 | 2004-08-03 | Ludwig Institute For Cancer Research | Endogenous retrovirus tumor associated nucleic acids and antigens |
| EP1586330A1 (en) | 2004-04-16 | 2005-10-19 | Georg-August-Universität Göttingen | Vaccination against malignant melanoma |
| DK1871391T3 (da) | 2005-03-30 | 2012-04-16 | Viroxis | Endogen retrovirus og proteiner, der kodes af env som target for cancerbehandling |
| AT502292B1 (de) * | 2005-05-11 | 2010-04-15 | Avir Green Hills Biotechnology | Melanomdiagnose |
| US8921050B2 (en) | 2006-03-17 | 2014-12-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of diagnosing renal cell carcinoma |
| US20080019979A1 (en) | 2006-05-22 | 2008-01-24 | Feng Wang-Johanning | HERV-K Antigens, Antibodies, and Methods |
| US20190351040A1 (en) * | 2017-02-01 | 2019-11-21 | Modernatx, Inc. | Rna cancer vaccines |
| BR112021006941A2 (pt) * | 2018-10-19 | 2021-08-31 | The Francis Crick Institute Limited | Antígenos de câncer inovadores e métodos |
| MX2021015765A (es) * | 2019-06-28 | 2022-01-27 | The Francis Crick Institute Ltd | Nuevos antigenos y metodos contra el cancer. |
| AU2020309202A1 (en) * | 2019-07-05 | 2021-12-09 | Enara Bio Limited | Novel cancer antigens and methods |
| CA3179694A1 (en) * | 2020-04-17 | 2021-10-21 | The Francis Crick Institute Limited | Fusion proteins of ctl antigens for treating melanoma |
-
2021
- 2021-04-19 JP JP2022562752A patent/JP2023522193A/ja active Pending
- 2021-04-19 EP EP21721983.1A patent/EP4136096A1/en active Pending
- 2021-04-19 WO PCT/GB2021/050940 patent/WO2021209775A1/en not_active Ceased
- 2021-04-19 CA CA3176754A patent/CA3176754A1/en active Pending
- 2021-04-19 CN CN202180029092.4A patent/CN115667288A/zh active Pending
-
2022
- 2022-10-14 US US18/046,670 patent/US20230302109A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7509504B2 (ja) | 免疫療法のためのコア／シェル構造プラットホーム | |
| Zhang et al. | Two-dimensional layered double hydroxide nanoadjuvant: recent progress and future direction | |
| US11338027B2 (en) | Fusion comprising a cell penetrating peptide, a multi epitope and a TLR peptide agonist for treatment of cancer | |
| Molino et al. | Viral-mimicking protein nanoparticle vaccine for eliciting anti-tumor responses | |
| JP6306593B2 (ja) | 細胞透過性ペプチド | |
| Sheng et al. | Cancer immunotherapy and nanomedicine | |
| JP2018509936A (ja) | 結腸直腸癌を治療するための細胞透過性ペプチド、カーゴ、及びｔｌｒペプチドアゴニストを含む新規複合体 | |
| CN110124018A (zh) | 一种模拟坏死肿瘤细胞的磷酸钙-脂质纳米疫苗及其应用 | |
| CN113557035B (zh) | 自组装肽纳米颗粒和其用途 | |
| Zeng et al. | Carrier-free nanovaccine: an innovative strategy for ultrahigh melanoma neoantigen loading | |
| Grippin et al. | Nanotechnology for immuno-oncology | |
| Gong et al. | Tumor Microenvironment‐Activated Hydrogel Platform with Programmed Release Property Evokes a Cascade‐Amplified Immune Response against Tumor Growth, Metastasis and Recurrence | |
| JP2022539157A5 (enExample) | ||
| JP2022539585A5 (enExample) | ||
| JP2022514116A5 (enExample) | ||
| JP2023522198A5 (enExample) | ||
| Wang et al. | A dissolvable microneedle platform for the delivery of tumor-derived total RNA nanovaccines for enhanced tumor immunotherapy | |
| JP2023522193A5 (enExample) | ||
| CN119587686A (zh) | 一种抗原肽聚合物囊泡肿瘤疫苗及其制备方法与应用 | |
| JP7561182B2 (ja) | ペプチドがロードされたキャリアシステムおよびその使用 | |
| Chen et al. | Nanovehicles for delivery of antigens and adjuvants as cancer nanovaccines | |
| Rajwar et al. | Validation of DoriVac (DNA origami vaccine) efficacy in a metastatic melanoma model | |
| Xie et al. | An mRNA Tumor Nanovaccine Expressing Tumor Antigen Fused With Angiotensin II Facilitates Type 1 Conventional Dendritic Cell‐Mediated Anti‐Tumor Immunity | |
| HK40105746A (en) | Core/shell structure platform for immunotherapy | |
| FR2822707A1 (fr) | Association d'un antigene tumoral et d'un systeme de delivrance d'une cytokine ou d'une chemokine a des fins d'immunotherapie du cancer |